Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

4 Discussion In this exploratory, post hoc pooled analysis of results from BROADWAY and BROOKLYN obicetrapib consistently demonstrated signals of attenuating renal function decline, including slower eGFR decline, fewer renal events, and a favorable trend in time-to-renal event analyses during a median 1 year of follow-up.

also in 1,335 other papers